MAP2K7 and renal cell carcinoma: To better define the effect of MAPK pathway inhibition, we examined 9 drugs with known MEK inhibitor activity (trametinib, selumetinib, AS703026, AZD8330, PD325901, CI-1040, TAK733, BIX02189, PD318088) in combination with dasatinib against the 5 VHL WT RCC cells (ACHN, SN12C, TK-10, UO-31, and CAKI-1) in our screen.